02319nas a2200421 4500000000100000008004100001260001700042653001500059653001000074653002100084653000900105653002900114653001000143653002100153653002100174653001100195653001100206653001000217653001100227653002300238653001200261653002500273653000900298653001600307653001700323653002600340653001700366653001600383653001600399100001500415700001500430245012400445300001100569490000700580050001800587520127800605022001401883 2004 d c2004 Oct-Dec10aAdolescent10aAdult10aAge Distribution10aAged10aAnti-Inflammatory Agents10aChild10aChild, Preschool10aErythema Nodosum10aFemale10aHumans10aIndia10aInfant10aLeprostatic Agents10aleprosy10aLeprosy, lepromatous10aMale10aMiddle Aged10aPrednisolone10aRetrospective Studies10aRisk Factors10aSex Factors10aThalidomide1 aSantaram V1 aPorichha D00aReaction cases treated at the Regional Leprosy Training and Research Institute, Aska, Orissa: a retrospective analysis. a310-200 v76 aSANTARAM 20043 a
This study is a retrospective analysis of 147 cases of leprosy reaction selected out of 942 cases of leprosy registered between 1992 and 2002 at the RLTRI, Aska (Orissa). The occurrence of reaction was about 16% with a slight increase over the years. There was a preponderance of males, with about 80% cases among males, and the peak occurrence of reaction was found in the age-group of 21-49 years. Reversal reaction (RR) was seen in 68.7% and ENL in 31.3% of cases. Single episode of RR and ENL reactions was seen in 61.2% and 43.5% respectively. In either type the last episode was seen even after about 32 months after RFT. There was a dissociation between nerve and skin manifestation, with both skin and nerve manifestation in 78.96%, skin lesions only in 21.1% and nerve lesions only in 50.9% of cases. About 88% of reaction was seen in MB patients, with a higher proportion of RR, because of inclusion of more borderline cases. Prednisolone was the drug of choice in both types of reaction, though in 17 cases of steroid dependency, thalidomide was proved to have an edge over steroids. Both types taken together, in half of the cases the first episode of reaction developed within 6 months of starting treatment. Multiple episodes were more common with ENL.
a0254-9395